Predictive and prognostic significance of tumor-infiltrating lymphocytes in patients with breast cancer treated with neoadjuvant systemic therapy

Despite the progress of tailored therapeutic strategies in patients with breast cancer, there is an unmet medical need for additional biomarkers that would guide therapy, including the administration of targeted agents. It has been demonstrated that the presence of tumor-infiltrating lymphocytes (TI...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2014-03, Vol.34 (3), p.1115-1125
Main Authors: Melichar, Bohuslav, Študentova, Hana, Kalábová, Hana, Vitásková, Denisa, Čermáková, Petra, Hornychová, Helena, Ryška, Aleš
Format: Article
Language:English
Subjects:
Breast Neoplasms - diagnosis
Breast Neoplasms - immunology
Breast Neoplasms - therapy
Female
Humans
Lymphocytes, Tumor-Infiltrating - immunology
Lymphocytes, Tumor-Infiltrating - pathology
Neoadjuvant Therapy
Prognosis
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Despite the progress of tailored therapeutic strategies in patients with breast cancer, there is an unmet medical need for additional biomarkers that would guide therapy, including the administration of targeted agents. It has been demonstrated that the presence of tumor-infiltrating lymphocytes (TILs) is associated with prognosis in patients with early breast cancer. Moreover, TIL counts were shown to predict outcome of neoadjuvant chemotherapy. The neoadjuvant setting is increasingly used to assess the efficacy of new systemic therapies, and TILs are promising as a biomarker reflecting the immune response to tumor. Future studies should investigate on the integration of TILs as predictive biomarkers in patients treated with targeted- agents.
ISSN:0250-7005
1791-7530